Theseus Pharmaceuticals — Investor Presentation (May 2023)
46 slides from Theseus Pharmaceuticals's investor presentation, May 25, 2023
Slide 1: Theseus Pharmaceuticals: A new generation of medicines to address cancer resistance
Theseus Pharmaceuticals A new generation of medicines to address cancer resistance May 2023 | THRX
Slide 2: Legal notice and forward-looking statements
Legal notice and forward-looking statements ©2023 Theseus Pharmaceuticals. Certain statements included in this presentation are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995.
Slide 3: Developing next-generation pan-variant TKI candidates for treatment-resistant cancer
©2023 Theseus Pharmaceuticals. Theseus is developing next-generation, single molecule pan-variant TKI candidates for treatment- resistant cancer Led by world-class R&D team with deep experience developing and commercializing novel targeted therapies in validated areas of unmet medical need Different
Slide 4: Executing on a novel pipeline of targeted therapies
Second program: THE-349 (EGFR-mutant NSCLC) Lead program: THE-630 (GIST) • KIT-driven GIST is a clonally heterogeneous disease which requires a pan-variant inhibitor to meaningfully improve patient outcomes • Enrolling patients in phase 1 portion of phase 1/2 study; preliminary dose escalation data
Slide 5: Experienced management team leveraging heritage of success
Bill Shakespeare, Ph.D. Co-founder, President of R&D Former VP Drug Discovery, ARIAD Experienced management team leveraging heritage of success Vic Rivera, Ph.D. Co-founder, CSO Former VP Preclinical & Translational Research, ARIAD David Kerstein, M.D. CMO Former CMO, Anchiano Former Sr. Med Dir, AR
Slide 6: Extensive experience and track record in TKI discovery, development, and commercialization
Extensive experience and track record in TKI discovery, development, and commercialization ©2023 Theseus Pharmaceuticals. Validated methodology & approach at ARIAD that produced three approved TKIs World-class team Leveraging prior achievements in the discovery, development and commercialization of
Slide 7: The problem
The problem ©2023 Theseus Pharmaceuticals. Tumor On-target resistance mutations emerge in response to targeted therapies, limiting the efficacy of such therapies Clonal heterogeneity develops over time, leading to disease complexity and tumor progression TKI = tyrosine kinase inhibitor. 7
Slide 8: Our solution
Our solution ©2023 Theseus Pharmaceuticals. Tumor Theseus’ next-generation, pan- variant TKIs are designed to simultaneously inhibit all major cancer-causing and resistance mutations, which has the potential to yield prolonged clinical benefit in early and late lines of treatment TKI = tyrosine kina
Slide 9: Theseus' approach: TKI candidates developed iteratively to optimize pan-variant activity
Theseus’ approach: TKI candidates are developed iteratively to optimize pan-variant activity ©2023 Theseus Pharmaceuticals. Structure-Guided Design In silico: Uses 3D structures of the target TK to design a TKI with multiple molecular touch points to maintain binding in the presence of any variants
Slide 10: Growing pipeline of targeted cancer therapies
Growing pipeline of targeted cancer therapies ©2023 Theseus Pharmaceuticals.Note: We hold a worldwide exclusive license to THE-630 in our therapeutic area of focus through the ARIAD License Agreement, as defined and described in our filings with the Securities and Exchange Commission. CML = Chronic
Slide 11: THE-630: Pan-variant KIT Inhibitor Candidate
THE-630: Pan-variant KIT Inhibitor Candidate
Slide 12: GIST is one of targeted oncology's great unmet patient needs
GIST is one of targeted oncology’s great unmet patient needs Sources: Corless, C. Modern Pathol 2014;27,s1-s16. GIST = Gastrointestinal Stromal Tumors. GIST is the most common sarcoma of the GI tract with ~4,000-6,000 new cases in the U.S. each year • ~80% of GIST patients present with an activating
Slide 13: 2L+ GIST progresses rapidly; current therapies are inadequate
2L+ GIST progresses rapidly; current therapies are inadequate Sources: Clarivate, DRG, Gleevec ® (imatinib) USPI, Sutent ® (sunitinib) USPI, Stivarga ® (regorafenib) USPI, Qinlock ® (ripretinib USPI). Stivarga ® ORR from Demetri, Lancet, 2013. 2L = Second Line. GIST = Gastrointestinal Stromal Tumors
Slide 14: Predictive Resistance Assay rationalizes deficiencies of approved KIT inhibitors
Our novel Predictive Resistance Assay™ rationalizes known deficiencies of approved KIT inhibitors for GIST Cav = average serum concentration, and is calculated as the Area Under the Curve, or AUC, over a 24-hour period and divided by 24. GIST = Gastrointestinal Stromal Tumors. Ex = exon. nM = nanomo
Slide 15: Pan-variant inhibitor is critical for effective treatment in 2L GIST
Clinical data suggest a pan-variant inhibitor is critical for effective treatment in patients with 2L GIST • 2L GIST is heterogeneous and remains a significant unmet need • INTRIGUE study demonstrated no difference in PFS between ripretinib and sunitinib because neither has coverage of both sets of
Slide 16: THE-630 could be the only therapy covering all major mutation classes
THE-630 could be the only therapy with coverage of all major classes of activating and resistance mutations ©2023 Theseus Pharmaceuticals.Based on data from our PRA (Predictive Resistance Assay™). PD = progressive disease. PR/CR = partial/complete response. SD = stable disease. (1) Assumes target Ca
Slide 17: Phase 1/2 trial design
Phase 1/2 trial design Phase 1 – Dose Escalation THE-630 once daily (QD) 3 + 3 dose escalation design Backfill enrollment (up to 40 patients) ≥5th Line cohort prior imatinib, sunitinib, regorafenib, and ripretinib (N=~20) 3rd-4th Line cohort prior imatinib and sunitinib, 0-1 additional lines of ther
Slide 18: Registration strategy for THE-630: rapidly advance to 2L
Registration strategy for THE-630: rapidly advance to 2L Targeting rapid advancement to 2L development, with plans to commence a 2L registrational study shortly after beginning our 5L registrational study Ongoing dose escalation Planned Phase 2 dose expansion Planned registrational studies Ongoing p
Slide 19: Standard 3+3 dose escalation design
Standard 3+3 dose escalation design • DLT evaluation period = 28 days • Dose level increases of up to 100% until one of the following: – Grade ≥ 2 non-hematologic or ≥ grade 3 hematological AE for which relationship to THE-630 cannot be ruled out – DLT – 48 mg dose level • Then, dose level increases
Slide 20: Baseline characteristics: heavily pretreated KIT-mutant GIST population
Baseline characteristics: heavily pretreated KIT-mutant GIST population 20 Demographics and Baseline Characteristics Total N=23 Median age, years 59 Female, n (%) 10 (43.5) ECOG Performance Status, n (%) 0 11 (47.8) 1 11 (47.8) 2 1 (4.3) Stage at Screening Stage IV, n (%) 23 (100) Number of unique p
Slide 21: Dose escalation (Cohorts 1-6)
Dose escalation (Cohorts 1-6) 21 AE = adverse event. C1D1 = Cycle 1 Day 1. Cav = average serum concentration. DLT = dose-limiting toxicity. ECOG Performance Status = Eastern Cooperative Oncology Group Performance Status. GIST = Gastrointestinal Stromal Tumors. PE = Pulmonary Embolism. QD = once dail
Slide 22: Safety profile supports continued dose escalation
Safety profile supports continued dose escalation • 65% of patients had treatment-related adverse events (AE) of any grade − Most common (≥10%) treatment- related AEs include fatigue, AST increased, diarrhea, nausea, dry mouth, and dyspnea − Treatment-related AEs were predominantly grade 1-2: of 89
Slide 23: Pharmacokinetics consistent with once-daily oral dosing
Pharmacokinetics consistent with once-daily oral dosing 23 • 3-6-fold accumulation observed from C1D1 to C1D15 • Approximately linear increase in systemic exposure at steady state through Cohort 6 - Cohort 5 (12 mg): mean Cav 46.6 nM with high inter-patient variability - Cohort 6 (18 mg): mean Cav 4
Slide 24: Prolonged stable disease observed at higher doses
Prolonged stable disease observed at higher doses 0 4 8 12 16 20 24 28 32 36 1 (4) 2 (5) 3 (5) 4 (4) 5 (4) 6 (4) 7 (3) 8 (3) 9 (8) 10 (4) 11 (4) 12 (6) 13 (4) 14 (4) 15 (2) 16 (3) 17 (2) 18 (2) 19 (4) 20 (4) 21 (4) 22 (4) 23 (3) Time on treatment (weeks) a Escalated to 6 mg in week 24 an
Slide 25: Reductions observed in KIT mutant allele fractions in ctDNA
8 315 76 11 122 5 4 16 14 712 11 51 2 14 16 12 4 15 16 165 1920 22 2219 19 19 1922191912 A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p A 50 2_ Y5 03 du p E5 54 _V 55 5d el W 55 7_ K5 58 de l M 55 2_ Y5 70 de l W 55 7_ V5 60 de lin sC W 55 7_ E5 62 de lin sV M 55 2_ E5 61 de lin sQ K 55 8_
Slide 26: Concomitant ctDNA reduction and stable disease at higher doses
17 11, 17 9 11, 17 11, 16, 17 11 11,13 9 11 (No post-BL) 11^, 134x, 142x, 1710x,18 (No post-BL) 11, 13 11, 132x,17 None detected in ctDNA 11, 17 9, 17 11, 173x 11##, 13## None detected in ctDNA 11^^, 133x, 172x, 19 9 To be analyzed 11†, 13, 14 To be analyzed Con
Slide 27: Clinical ctDNA observations consistent with PRA predictions
Clinical ctDNA observations consistent with PRA predictions Clinical ctDNA observed in trial Target (~40 mg) Cohort 5/6 (12/18 mg) Cohort 4 (9 mg) Cohort 3 (6 mg) Cohort 2 (4 mg) Cohort 1 (3 mg) ctDNA effects shown are the best fold change in mutant allele frequency (MAF). ctDNA = circulating tumor
Slide 28: THE-630 building the foundation for a best-in-class KIT inhibitor for GIST
THE-630 – building the foundation for a best-in-class KIT inhibitor for patients with GIST 28 Next data update expected Q4 2023 Part 2: Dose expansion (2L, 3L/4L, 5L) 2L = Second Line. 3L = Third Line. 4L = Fourth Line. 5L = Fifth Line. ctDNA = circulating tumor DNA. mPFS = median progression free s
Slide 29: THE-349: Fourth-Generation EGFR Inhibitor Candidate
THE-349: Fourth-Generation EGFR Inhibitor Candidate
Slide 30: EGFRm NSCLC overview
EGFRm NSCLC overview 30 ©2023 Theseus Pharmaceuticals. There is no approved TKI to address all combinations of major EGFR activating and resistance mutations • EGFR mutations are a key driver of NSCLC, with approximately 18,000 first-line EGFRm NSCLC patients in the United States with mutations in e
Slide 31: Treatment paradigm for EGFRm NSCLC
Treatment paradigm for EGFRm NSCLC 31 ©2023 Theseus Pharmaceuticals. Exon 19 deletion (D) or L858R (L) activating mutation EGFR mutation T790M resistance mutation (T) + D or L = DT or LT C797S resistance mutation (C) + D or L = DC or LC C797S resistance mutation (C) + DT or LT = DTC or LTC • Selecti
Slide 32: THE-349 potently inhibits single-, double-, and triple-mutants
Preclinical data has demonstrated THE-349 potently inhibits single-, double-, and triple-mutants, including T790M and C797S 32 ©2023 Theseus Pharmaceuticals. Mutational Coverage L858R or Exon 19 del L858R or Exon 19 del + T790M L858R or Exon 19 del + C797S L858R or Exon 19 del + T790M + C797S THE-34
Slide 33: THE-349 potent and selective EGFR mutant activity with kinome selectivity
THE-349 exhibits potent and selective EGFR mutant activity with significant kinome selectivity in vitro 33 ©2023 Theseus Pharmaceuticals. THE-349 demonstrates low nanomolar IC50 values against single-, double- and triple-mutant EGFR variants with wild-type selectivity which exceeds that of erlotinib
Slide 34: THE-349 robust tumor regression in mouse models
THE-349 has robust tumor regression activity in mouse models expressing EGFR single-, double- and triple-mutant variants at well- tolerated doses 34 ©2023 Theseus Pharmaceuticals.Note: Data from the 2022 EORTC-NCI-AACR (ENA) Symposium. Poster #236. EGFR = Epidermal Growth Factor Receptor. TGI = tumo
Slide 35: THE-349 deep, durable regressions in osimertinib-resistant PDX model
THE-349 induced deep, durable regressions in clonally heterogeneous osimertinib-resistant PDX model Model developed from patient with NSCLC after failure of >5 lines of therapy (including erlotinib and osimertinib) • Model reflects clonal heterogeneity – mixture of DTC and original D primary mutatio
Slide 36: THE-349 is active in CNS with favorable drug-like properties
THE-349 is active in CNS and has displayed favorable drug-like properties in mouse models 36 ©2023 Theseus Pharmaceuticals.Note: Data from the 2022 EORTC-NCI-AACR (ENA) Symposium. Poster #236. CNS = central nervous system. EGFR = Epidermal Growth Factor Receptor. NSCLC = Non-Small Cell Lung Cancer.
Slide 37: Clinical development plan for THE-349
Clinical development plan for THE-349 37 ©2023 Theseus Pharmaceuticals. Theseus plans to pursue an initial registration as monotherapy in patients with on-target resistance, as well as rapidly expand into evaluation of combinations and, if clinical data support, target the broader 2L market, which c
Slide 38: BCR-ABL Program
@) THESEUS BCR-ABL Program
Slide 39: Approved BCR-ABL inhibitors have limitations in balancing efficacy and safety
Approved BCR-ABL inhibitors have limitations because they do not optimally balance efficacy and safety 39 ©2023 Theseus Pharmaceuticals. Generation Safety/tolerability(1) Efficacy/pan-ness(2) CML Indication Adult Ph+ ALL Indication Target Product Profile for Theseus BCR-ABL Inhibitor 5G ≥2L (target)
Slide 40: Key features of CML
Key features of CML 40 ©2023 Theseus Pharmaceuticals. • Disease remains BCR-ABL driven through multiple lines of therapy, and patients commonly will relapse with a BCR-ABL resistance mutation • Multiple therapies have been approved; however, approximately 30% to 40% of patients started on any TKI wi
Slide 41: Key features of adult Ph+ ALL
Key features of adult Ph+ ALL 41 ©2023 Theseus Pharmaceuticals. • Newly diagnosed adults have historically received chemotherapy followed by allogeneic hematopoietic stem-cell transplant (HSCT), and more recently the addition of BCR-ABL TKIs have improved outcomes in 1L treatment, despite their lack
Slide 42: Target product profile for Theseus' pan-variant BCR-ABL TKI
Target product profile for Theseus’ pan-variant BCR-ABL TKI 42 ©2023 Theseus Pharmaceuticals. Compound Company Generation 2021 FY Sales (USD) Imatinib (Gleevec®) Novartis 1G $1.0bn Dasatinib (Sprycel®) Bristol Myers Squibb 2G $2.1bn Nilotinib (Tasigna®) Novartis 2G $2.0bn Bosutinib (Bosulif®) Pfizer
Slide 43: In vitro pan-BCR-ABL activity with increased selectivity versus ponatinib
In vitro characterization demonstrated pan-BCR-ABL activity with increased selectivity versus ponatinib 43 ©2023 Theseus Pharmaceuticals. On-target BCR-ABL potency (BaF3 IC50 nM) Off-target potency (BaF3 IC50 nM) Endothelial cell tox (IC25 nM) Kinome selectivity Cmpd WT T315I E255V F359V KDR FLT3 FG
Slide 44: Similar tumor regression and superior tolerability to ponatinib in vivo
Theseus molecule showed similar tumor regression activity and superior tolerability to ponatinib in vivo 44 ©2023 Theseus Pharmaceuticals. Activity against most recalcitrant mutant (E255V) Compound 1 induced strong tumor regressions against the most recalcitrant mutant and demonstrated improved tole
Slide 45: Executing on a novel pipeline of targeted therapies
Second program: THE-349 (EGFR-mutant NSCLC) Lead program: THE-630 (GIST) • KIT-driven GIST is a clonally heterogeneous disease which requires a pan-variant inhibitor to meaningfully improve patient outcomes • Enrolling patients in phase 1 portion of phase 1/2 study; preliminary dose escalation data
Slide 46: © THESEUS
© THESEUS
Theseus Pharmaceuticals — Investor Presentation (May 2023) on 6ix